Processa PharmaceuticalsPCSA
13F holders, Q1 2025 (March 31)9holders +1
2new positions
1sold out
$0.37avg. 13F price*
At the end of Q1 2025, 9 institutions reported holding Processa Pharmaceuticals Inc. (PCSA) in their 13F filings, up 1 from Q4 2024. 2 opened new positions and 1 sold out. The largest holders were Armistice Capital, LLC ($21K), Virtu Financial LLC ($16K) and Geode Capital Management, LLC ($13K).
- Company
- Processa Pharmaceuticals Inc.
- CUSIP
- 74275C304
- Latest filing quarter
- Q3 2025
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $37K |
| Exits | 1 | $28K |
All 13F filers, Q4 2024 → Q1 2025: 111,677 shares bought and 39,823 shares sold, net +71,854 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 9 holders
| Armistice Capital, LLC | 0.00% | New | 56,000 | $21K |
| Virtu Financial LLC | 0.00% | New | 43,229 | $16K |
| Geode Capital Management, LLC | 0.00% | Add +56.5% | 34,413 | $13K |
| Vanguard Group Inc. | 0.00% | No change | 24,433 | $9K |
| Composition Wealth, LLC | 0.00% | No change | 10,000 | $4K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +0.2% | 2,467 | $913 |
| Wells Fargo & Company | 0.00% | No change | 154 | $57 |
| UBS Group AG | 0.00% | Reduce -99.3% | 56 | $21 |
| Bank of America Corp. | 0.00% | Add +48.0% | 37 | $14 |
"% of holder's portfolio" is PCSA's weight in each manager's 13F, not the share of Processa Pharmaceuticals Inc. the manager owns.